Open AccessStudy of Antimicrobial Utilization and Cost of Therapy in Medicine Intensive Care Unit of a Tertiary Care Hospital in Eastern India
Author(s) -
Shantanu K Patra,
Shakti Bedanta Mishra,
Arun Rath,
Samir Samal,
Sheikh Nurul Iqbal
Publication year - 2020
Publication title -
indian journal of critical care medicine/indian journal of critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 30
eISSN - 1998-359X
pISSN - 0972-5229
DOI - 10.5005/jp-journals-10071-23552
Subject(s) - medicine , interquartile range , emergency medicine , medical prescription , tazobactam , intensive care unit , observational study , piperacillin , meropenem , apache ii , antimicrobial stewardship , defined daily dose , intensive care medicine , antibiotic resistance , imipenem , antibiotics , genetics , pseudomonas aeruginosa , bacteria , microbiology and biotechnology , pharmacology , biology
High utilization of antimicrobial agent (AMA) and inappropriate usage in an intensive care unit (ICU) intensifies resistant organism, morbidity, mortality, and treatment cost. Prescription audit and active feedback are a proven method to check the irrational prescription. To analyze and compare the utilization of drugs, the World Health Organization (WHO) proposed daily defined dose (DDD)/100 patient days and days of therapy (DOT)/100 patient days to measure utilization of AMAs. Data of AMAs utilization are required for planning an antibiotic policy and for follow-up of intervention strategies.